nct_id string | updated_at timestamp[us] | brief_title string | official_title string | acronym string | study_type string | overall_status string | study_first_submit_date timestamp[ms] | start_date timestamp[ms] | primary_completion_date timestamp[ms] | completion_date timestamp[ms] | phases sequence | enrollment_count float64 | minimum_age float64 | maximum_age float64 | sex string | healthy_volunteers bool | brief_summary string | detailed_description string | eligibility_criteria string | lead_sponsor_name string | lead_sponsor_class string | org_study_id_info dict | why_stopped string | expanded_access_info dict | last_update_submit_qc_date timestamp[ms] | last_update_post_date_struct dict | study_first_post_date_struct dict | std_ages sequence | study_population string | sampling_method string | oversight_has_dmc bool | design_info dict | conditions sequence | keywords string | interventions null | locations list | collaborators list | arm_groups null | outcomes dict | overall_officials list | study_references string | misc_info_module string | condition_browse_module dict | intervention_browse_module dict | mesh_terms dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT01273766 | null | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload | None | INTERVENTIONAL | COMPLETED | 2011-01-07T00:00:00 | null | null | null | [
"PHASE2"
] | 16 | 18 | null | ALL | false | RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions.
PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies. | PRIMARY OBJECTIVES: I. To determine the effects of the iron-chelating agent deferasirox on changes in: neutrophil function; macrophage function; lymphocyte function.
SECONDARY OBJECTIVES: I. To determine the effect of chelation on the incidence of bacterial, viral and fungal infections documented by clinical, microbio... | Inclusion Criteria:
* Patients must have a pathology confirmed diagnosis of one of the following: myelodysplastic syndrome (MDS); acute leukemia; multiple myeloma; myelofibrosis; lymphoma; chronic anemia; sickle cell anemia
* Iron score \>= 2
* Absolute Neutrophil Count (ANC) \>= 1,000
* Platelets \>= 50,000
* Albumin... | Wake Forest University Health Sciences | OTHER | {
"id": "IRB00015287",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2011-01-07T00:00:00 | {
"date": "2018-09-07",
"type": "ACTUAL"
} | {
"date": "2011-01-10",
"type": "ESTIMATED"
} | [
"ADULT",
"OLDER_ADULT"
] | null | null | true | {
"allocation": "NON_RANDOMIZED",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "SUPPORTIVE_CARE",
"timePerspective": null
} | [
"Acute Undifferentiated Leukemia",
"Adult Acute Lymphoblastic Leukemia in Remission",
"Adult Acute Myeloid Leukemia in Remission",
"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
"Adult Acute Myeloid Leukemia With Del(5q)",
"Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
"Adult Acut... | null | null | [
{
"city": "Winston-Salem",
"country": "United States",
"facility": "Comprehensive Cancer Center of Wake Forest University",
"geoPoint": {
"lat": 36.09986,
"lon": -80.24422
},
"state": "North Carolina"
}
] | [
{
"class": "NIH",
"name": "National Cancer Institute (NCI)"
}
] | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only)",
"timeFrame": "Baseline, up to 6 months"
}
],
"secondary": [
{
"description": null,
"measure": ... | [
{
"affiliation": "Wake Forest University Health Sciences",
"name": "Mary Ann Knovich, MD",
"role": "PRINCIPAL_INVESTIGATOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D004194",
"term": "Disease"
},
{
"id": "D010335",
"term": "Pathologic Processes"
},
{
"id": "D009370",
"term": "Neoplasms by Histologic Type"
},
{
"id": "D009369",
"term": "Neoplasms"
},
{
"id": "D00823... | {
"ancestors": [
{
"id": "D007502",
"term": "Iron Chelating Agents"
},
{
"id": "D002614",
"term": "Chelating Agents"
},
{
"id": "D064449",
"term": "Sequestering Agents"
},
{
"id": "D045504",
"term": "Molecular Mechanisms of Pharmacological Ac... | {
"conditions": [
{
"id": "D002051",
"term": "Burkitt Lymphoma"
},
{
"id": "D009181",
"term": "Mycoses"
},
{
"id": "D008223",
"term": "Lymphoma"
},
{
"id": "D007938",
"term": "Leukemia"
},
{
"id": "D007951",
"term": "Leuke... |
NCT00787566 | null | Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting | A Randomized, Single Administration, Double-blind, Parallel-group Phase 2 Dose Finding Study to Assess the Efficacy, Tolerability, and Safety of TRG (Intranasal Granisetron) in Patients With Chemotherapy-induced Nausea and Vomiting (CINV) Associated With the Administration of Highly Emetogenic Chemotherapy | None | INTERVENTIONAL | COMPLETED | 2008-11-05T00:00:00 | null | null | null | [
"PHASE2"
] | 68 | 18 | null | ALL | false | Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV) associated with the administration of highly emetogenic chemotherapy.
Primary Objective: ... | null | Inclusion Criteria:
* Patients with histologically and/or cytologically confirmed cancer
* ECOG performance status of 0, 1, or 2
* Patients with life expectancy of at least 3 months
* Patients who are chemotherapy naïve
* Patients who will be receiving the first cycle of a highly emetogenic regimen according to the MA... | Shin Nippon Biomedical Laboratories, Ltd. | INDUSTRY | {
"id": "TRG-002",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2008-11-06T00:00:00 | {
"date": "2011-07-12",
"type": "ESTIMATED"
} | {
"date": "2008-11-07",
"type": "ESTIMATED"
} | [
"ADULT",
"OLDER_ADULT"
] | null | null | null | {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": null,
"whoMasked": [
"PARTICIPANT",
"CARE_PROVIDER",
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPu... | [
"Chemotherapy-Induced Nausea and Vomiting"
] | ["Highly emetogenic chemotherapy induced nausea and vomiting"] | null | [
{
"city": "The study is managed by Kendle International, in Wilmington",
"country": "United States",
"facility": "The study is conducted at 14 Centers, in 14 cities accross the United States",
"geoPoint": null,
"state": "North Carolina"
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Percentage of Patients With Complete Control",
"timeFrame": "24 hours"
}
],
"secondary": [
{
"description": null,
"measure": "Percentage of Patients With Complete Response",
"timeFrame": "24 hours"
... | null | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D012817",
"term": "Signs and Symptoms, Digestive"
}
],
"browseBranches": [
{
"abbrev": "BC23",
"name": "Symptoms and General Pathology"
},
{
"abbrev": "All",
"name": "All Conditions"
}
],
"browseLeaves": [
{
"asFou... | {
"ancestors": [
{
"id": "D000932",
"term": "Antiemetics"
},
{
"id": "D001337",
"term": "Autonomic Agents"
},
{
"id": "D018373",
"term": "Peripheral Nervous System Agents"
},
{
"id": "D045505",
"term": "Physiological Effects of Drugs"
},
... | {
"conditions": [
{
"id": "D009325",
"term": "Nausea"
},
{
"id": "D014839",
"term": "Vomiting"
}
],
"interventions": [
{
"id": "D017829",
"term": "Granisetron"
}
]
} |
NCT00497666 | null | Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study | Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study | None | OBSERVATIONAL | UNKNOWN | 2007-07-06T00:00:00 | null | null | null | null | null | 18 | 90 | ALL | null | Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropa... | Background Type 2 diabetes mellitus is a public health concern, and projections of its future effect are alarming. According to the World Health Organization, diabetes affects more than 170 million people worldwide, and this number will rise to 370 million by 2030 \[1\]. About one third of those affected will eventuall... | Inclusion Criteria:
1. Diagnosis of Diabetes Mellitus Type II
2. Treatment With Oral hypoglycemics
3. Availability of Baseline and follow up clinical data
Exclusion Criteria:
1. Insulin Therapy at baseline
2. Malignancy | Assaf-Harofeh Medical Center | OTHER_GOV | {
"id": "346147Rosi",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2007-07-06T00:00:00 | {
"date": "2007-07-09",
"type": "ESTIMATED"
} | {
"date": "2007-07-09",
"type": "ESTIMATED"
} | [
"ADULT",
"OLDER_ADULT"
] | null | null | false | {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "OTHER"
} | [
"Diabetes",
"Diabetic Nephropathy",
"Renal Protection"
] | ["Diabetes", "Diabetic nephropathy", "renal protection"] | null | [
{
"city": "Zerifin,",
"country": "Israel",
"facility": "Clalit Health Cervices, Central District",
"geoPoint": {
"lat": 31.95857,
"lon": 4.83723
},
"state": null
}
] | null | null | null | [
{
"affiliation": "Nephrology Division, Assaf Harofeh Medical Center, Zerifin,",
"name": "Leonid S Feldman",
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"affiliation": "Assaf-Harofeh Medical Center",
"name": "Leonid S Feldman",
"role": "PRINCIPAL_INVESTIGATOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D014570",
"term": "Urologic Diseases"
},
{
"id": "D052776",
"term": "Female Urogenital Diseases"
},
{
"id": "D005261",
"term": "Female Urogenital Diseases and Pregnancy Complications"
},
{
"id": "D000091642",
"term":... | {
"ancestors": null,
"browseBranches": [
{
"abbrev": "Hypo",
"name": "Hypoglycemic Agents"
},
{
"abbrev": "All",
"name": "All Drugs and Chemicals"
}
],
"browseLeaves": [
{
"asFound": null,
"id": "M1677",
"name": "Rosiglitazone",
"relevance": "L... | {
"conditions": [
{
"id": "D007674",
"term": "Kidney Diseases"
},
{
"id": "D003928",
"term": "Diabetic Nephropathies"
},
{
"id": "D018450",
"term": "Disease Progression"
}
],
"interventions": []
} |
NCT01978366 | null | Open Label Extension Study of HT-100 in Patients With DMD | An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01 | None | INTERVENTIONAL | TERMINATED | 2013-10-31T00:00:00 | null | 2016-04-30T00:00:00 | 2016-04-30T00:00:00 | [
"PHASE2"
] | 17 | 6 | 20 | MALE | false | This study is designed to provide 6-months continuous dosing with the study medication, called HT-100, on participants who successfully completed the predecessor study (HALO-DMD-01). The main purpose of this study is to assess chronic safety, tolerability, pharmacodynamic activity (testing the drug's effect on DMD) and... | null | Inclusion Criteria:
* Completed both the single ascending dose (SAD) and multiple ascending dose (MAD) phases of predecessor study HALO-DMD-01
* Maintained the same corticosteroid therapy from the predecessor study HALO-DMD-01
* Ability to provide written informed consent
* Ambulatory or non-ambulatory
Exclusion Crit... | Processa Pharmaceuticals | INDUSTRY | {
"id": "HALO-DMD-02",
"link": null,
"type": null
} | Dosing stopped | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2013-10-31T00:00:00 | {
"date": "2020-09-03",
"type": "ACTUAL"
} | {
"date": "2013-11-07",
"type": "ESTIMATED"
} | [
"CHILD",
"ADULT"
] | null | null | true | {
"allocation": "NON_RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
} | [
"Duchenne Muscular Dystrophy"
] | ["Duchenne muscular dystrophy", "halofuginone hydrobromide", "anti-fibrotic", "anti-inflammatory", "muscle regeneration", "protein synthesis inhibitor"] | null | [
{
"city": "Sacramento",
"country": "United States",
"facility": "University of California, Davis Medical Center",
"geoPoint": {
"lat": 38.58157,
"lon": -121.4944
},
"state": "California"
},
{
"city": "Baltimore",
"country": "United States",
"facility": "Kennedy Kr... | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Safety and tolerability of administration of 6 months of chronic, oral, multiple doses of HT-100 to boys with DMD.",
"timeFrame": "Months 2, 4, 6, 7"
}
],
"secondary": [
{
"description": null,
"measure": "... | [
{
"affiliation": "AkashiTherapeutics",
"name": "Diana M Escolar, MD",
"role": "STUDY_DIRECTOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D020966",
"term": "Muscular Disorders, Atrophic"
},
{
"id": "D009135",
"term": "Muscular Diseases"
},
{
"id": "D009140",
"term": "Musculoskeletal Diseases"
},
{
"id": "D009468",
"term": "Neuromuscular Diseases"
}... | {
"ancestors": [
{
"id": "D000970",
"term": "Antineoplastic Agents"
},
{
"id": "D003049",
"term": "Coccidiostats"
},
{
"id": "D000981",
"term": "Antiprotozoal Agents"
},
{
"id": "D000977",
"term": "Antiparasitic Agents"
},
{
"id... | {
"conditions": [
{
"id": "D009136",
"term": "Muscular Dystrophies"
},
{
"id": "D020388",
"term": "Muscular Dystrophy, Duchenne"
}
],
"interventions": [
{
"id": "C010176",
"term": "Halofuginone"
}
]
} |
NCT01971866 | null | Camera Based System to Monitor Patient Movement During Radiation Treatment | Improving Safety and Accuracy of Proton Therapy by Use of Camera-Based Patient Localization System | DS02 | OBSERVATIONAL | TERMINATED | 2013-10-17T00:00:00 | null | null | null | null | 1 | 18 | null | ALL | false | This study aims to investigate the advantages of using AlignRT, a commercially available, FDA approved camera-based imaging system for proton therapy patients prior to and during their radiation treatment delivery. | null | Inclusion Criteria:
Patients with tumors of the brain, head and neck, thorax, upper abdomen, posterior spine/sacrum and extremities | University of Florida | OTHER | {
"id": "UFPTI 1215-DS02",
"link": null,
"type": null
} | Slow enrollment, feasibility issues | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2013-10-23T00:00:00 | {
"date": "2016-01-27",
"type": "ESTIMATED"
} | {
"date": "2013-10-29",
"type": "ESTIMATED"
} | [
"ADULT",
"OLDER_ADULT"
] | Patients who are undergoing proton radiation therapy at UFPTI | NON_PROBABILITY_SAMPLE | true | {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_ONLY",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
} | [
"Set up and Monitoring of Patients Receiving Proton Radiation"
] | ["Proton radiation", "AlignRT"] | null | [
{
"city": "Jacksonville",
"country": "United States",
"facility": "University of Florida Proton Therapy Institute",
"geoPoint": {
"lat": 30.33218,
"lon": -81.65565
},
"state": "Florida"
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Paired difference between image accuracy plan data from the AlignRT system compared to the current x-ray based imaging system.",
"timeFrame": "3 months"
}
],
"secondary": null
} | [
{
"affiliation": "University of Florida Proton Therapy Institute",
"name": "Maria Mamalui-Hunter, PhD",
"role": "PRINCIPAL_INVESTIGATOR"
}
] | null | {"versionHolder": "2025-06-18"} | null | null | null |
NCT04912466 | null | IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors. | A Phase 1a/1b Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors. | None | INTERVENTIONAL | COMPLETED | 2021-05-28T00:00:00 | null | 2022-12-03T00:00:00 | 2023-08-25T00:00:00 | [
"PHASE1"
] | 61 | 18 | 75 | ALL | false | The Phase Ia study was designed to evaluate the tolerability, safety, PK, PD, immunogenicity and primary resistance of single therapy tumor activity in subjects with advanced or metastatic solid tumors who have failed standard treatment. Phase Ib study was designed to evaluate the safety and initial efficacy of IBI322 ... | null | Inclusion Criteria:
1. Histologically/cytologically confirmed, locally advanced unresectable or metastatic tumors.
2. Per RECIST1, at least one evaluable or measurable lesion.
3. Male or female subject above 18 years old, no more than 75 years old.
4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) per... | Innovent Biologics (Suzhou) Co. Ltd. | INDUSTRY | {
"id": "CIBI322A105",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2021-05-28T00:00:00 | {
"date": "2023-09-06",
"type": "ACTUAL"
} | {
"date": "2021-06-03",
"type": "ACTUAL"
} | [
"ADULT",
"OLDER_ADULT"
] | null | null | false | {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
} | [
"Advanced Solid Tumor"
] | null | null | [
{
"city": "Jinan",
"country": "China",
"facility": "Shandong Province Cancer Hospital",
"geoPoint": {
"lat": 36.66833,
"lon": 116.99722
},
"state": "Shandong"
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Number of DLT",
"timeFrame": "21 Days"
},
{
"description": null,
"measure": "Number of treatment related AEs",
"timeFrame": "up to 90 days post last dose"
},
{
"description": null,
"m... | [
{
"affiliation": "No.440, Jiyan Road, Jinang City, Shandong Province, China",
"name": "Jinming Yu, M.D.",
"role": "PRINCIPAL_INVESTIGATOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": null,
"browseBranches": null,
"browseLeaves": null,
"meshes": [
{
"id": "D009369",
"term": "Neoplasms"
}
]
} | {
"ancestors": null,
"browseBranches": [
{
"abbrev": "All",
"name": "All Drugs and Chemicals"
}
],
"browseLeaves": [
{
"asFound": null,
"id": "M10184",
"name": "Immunoglobulins",
"relevance": "LOW"
},
{
"asFound": null,
"id": "M4225",
"na... | {
"conditions": [
{
"id": "D009369",
"term": "Neoplasms"
}
],
"interventions": []
} |
NCT03409666 | null | Randomized Controlled RSA Study Comparing the Taperloc Complete Versus the Taperloc Complete Microplasty. | Randomized Controlled Study Comparing the Taperloc Complete Versus the Taperloc Complete Microplasty. | None | INTERVENTIONAL | COMPLETED | 2018-01-08T00:00:00 | null | 2020-11-06T00:00:00 | 2020-11-06T00:00:00 | [
"NA"
] | 50 | 18 | 70 | ALL | false | This is a single center, prospective, randomized controlled study. The primary objective of this study is to measure migration over two years with RSA. Patients will be randomized in two arms, receiving a Taperloc Complete Reduced Distal or a Taperloc Complete Microplasty hip stem. | A total of 50 patients will be enrolled into the study, randomized 1:1. All patients will receive a G7 limited hole acetabular cup with E1 liner.
All potential study subjects will be required to participate in the Informed Consent process. | Inclusion Criteria:
* Non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis and rheumatoid arthritis.
* Correction of functional deformity.
* Male or female
-≥ 18 and ≤ 70 years of age
* Subjects willing to return for follow-up evaluations.
* Subjects able to read and understand D... | Zimmer Biomet | INDUSTRY | {
"id": "ORTHO.CR.GH60",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2018-01-17T00:00:00 | {
"date": "2022-07-14",
"type": "ACTUAL"
} | {
"date": "2018-01-24",
"type": "ACTUAL"
} | [
"ADULT",
"OLDER_ADULT"
] | null | null | false | {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "1:1 assignment of treatment",
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": nul... | [
"Hip Osteoarthritis",
"Noninflammatory Degenerative Joint Disease",
"Avascular Necrosis",
"Correction of Functional Deformity",
"Rheumatoid Arthritis"
] | ["Total Hip Arthroplasty", "Medical Device", "Performance", "Safety", "Hip prosthesis", "Roentgen Stereophotogrammetric Analysis"] | null | [
{
"city": "Roosendaal",
"country": "Netherlands",
"facility": "Bravis",
"geoPoint": {
"lat": 51.53083,
"lon": 4.46528
},
"state": null
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Stability Over a Period of Two Year Measured by Migration With Röntgen Stereophotogrammetric Analysis (RSA)",
"timeFrame": "2 years postoperatively"
}
],
"secondary": [
{
"description": null,
"measure": "D... | [
{
"affiliation": "Zimmer Biomet",
"name": "Paola Vivoda, BSc",
"role": "STUDY_DIRECTOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D001168",
"term": "Arthritis"
},
{
"id": "D009140",
"term": "Musculoskeletal Diseases"
},
{
"id": "D012216",
"term": "Rheumatic Diseases"
},
{
"id": "D010335",
"term": "Pathologic Processes"
}
],
"browseBranc... | null | {
"conditions": [
{
"id": "D010003",
"term": "Osteoarthritis"
},
{
"id": "D007592",
"term": "Joint Diseases"
},
{
"id": "D015207",
"term": "Osteoarthritis, Hip"
},
{
"id": "D009336",
"term": "Necrosis"
}
],
"interventions": null
} |
NCT00622466 | null | Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer | Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer | None | INTERVENTIONAL | TERMINATED | 2008-02-22T00:00:00 | null | null | null | [
"PHASE2"
] | 20 | 18 | null | ALL | false | RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.... | OBJECTIVES:
Primary
* To evaluate the efficacy of sorafenib tosylate and paclitaxel by measuring tumor response, as defined by RECIST criteria, in patients with metastatic, HER2-negative breast cancer.
Secondary
* To evaluate time to disease progression in patients treated with this regimen.
* To evaluate six-month... | DISEASE CHARACTERISTICS:
Inclusion criteria:
* Histologically\* confirmed breast cancer
* Stage IV (metastatic) disease
* Radiographic evidence of metastases NOTE: \*Histological confirmation of the actual metastasis is not required.
* Measurable disease by RECIST criteria defined as ≥ 1 unidimensionally meas... | University of Texas Southwestern Medical Center | OTHER | {
"id": "STU 082010-161",
"link": null,
"type": null
} | Study sponsor requested that the study be permanently closed by letter. | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2008-02-22T00:00:00 | {
"date": "2020-10-19",
"type": "ACTUAL"
} | {
"date": "2008-02-25",
"type": "ESTIMATED"
} | [
"ADULT",
"OLDER_ADULT"
] | null | null | true | {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
} | [
"Breast Cancer"
] | ["stage IV breast cancer", "male breast cancer", "recurrent breast cancer", "HER2-negative breast cancer"] | null | [
{
"city": "Dallas",
"country": "United States",
"facility": "University of Texas Southwestern Medical Center",
"geoPoint": {
"lat": 32.78306,
"lon": -96.80667
},
"state": "Texas"
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Time to Tumor Progression",
"timeFrame": "Time from first treatment to disease progression or death (up to 36 months)"
}
],
"secondary": [
{
"description": null,
"measure": "Tumor Response Rate",
"ti... | [
{
"affiliation": "Simmons Cancer Center",
"name": "Barbara B. Haley, MD",
"role": "PRINCIPAL_INVESTIGATOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D009371",
"term": "Neoplasms by Site"
},
{
"id": "D009369",
"term": "Neoplasms"
},
{
"id": "D001941",
"term": "Breast Diseases"
},
{
"id": "D012871",
"term": "Skin Diseases"
}
],
"browseBranches": [
{
... | {
"ancestors": [
{
"id": "D000972",
"term": "Antineoplastic Agents, Phytogenic"
},
{
"id": "D000970",
"term": "Antineoplastic Agents"
},
{
"id": "D050257",
"term": "Tubulin Modulators"
},
{
"id": "D050256",
"term": "Antimitotic Agents"
},... | {
"conditions": [
{
"id": "D001943",
"term": "Breast Neoplasms"
}
],
"interventions": [
{
"id": "D017239",
"term": "Paclitaxel"
},
{
"id": "D000077157",
"term": "Sorafenib"
}
]
} |
NCT03807466 | null | Feedback to Improve Rational Strategies of Antibiotic Initiation and Duration in Long Term Care | Feedback to Improve Rational Strategies of Antibiotic Initiation and Duration in Long Term | FIRST AID-LTC | INTERVENTIONAL | COMPLETED | 2019-01-15T00:00:00 | null | 2020-04-30T00:00:00 | 2021-03-31T00:00:00 | [
"NA"
] | 356 | null | null | ALL | false | There is a high rate of inappropriate antibiotic use in long-term care (LTC) facilities, with both unnecessary initiation and prolongation of treatments. Although there are challenges to rational antibiotic use in LTC, the variability in antibiotic initiation and use of prolonged treatment durations is driven by prescr... | Overarching Goals
The overarching goals of FIRST AID - LTC are two-fold:
1. Improve rational antibiotic prescribing by physicians to minimize harms among LTC residents.
2. Advance the science of audit-and-feedback to improve physician prescribing practices.
Specific Aims
To improve rational antibiotic prescribing i... | To Identify an LTC Resident
Inclusion Criteria:
An individual having a minimum of 2 records on separate days within the quarter meeting any combination of the following criteria:
* a record for a non-emergency long-term care inpatient services OR
* an Ontario Drug Benefits record administered in long-term care
Inde... | Institute for Clinical Evaluative Sciences | OTHER | {
"id": "441-2017",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2019-01-15T00:00:00 | {
"date": "2021-08-25",
"type": "ACTUAL"
} | {
"date": "2019-01-17",
"type": "ACTUAL"
} | [
"CHILD",
"ADULT",
"OLDER_ADULT"
] | null | null | true | {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": "Assess two interventional parallel study models consisting of two intervention arms each",
"maskingInfo": {
"masking": "TRIPLE",
"maskingDescription": "The team at Health Quality Ontario will be aware of the ... | [
"Antibiotic Initiation",
"Antibiotic Duration"
] | null | null | [
{
"city": "Toronto",
"country": "Canada",
"facility": "ICES",
"geoPoint": {
"lat": 43.70011,
"lon": -79.4163
},
"state": "Ontario"
}
] | [
{
"class": "OTHER_GOV",
"name": "Canadian Institutes of Health Research (CIHR)"
},
{
"class": "OTHER_GOV",
"name": "Ontario Agency for Health Protection and Promotion"
},
{
"class": "OTHER",
"name": "Health Quality Ontario"
}
] | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Antibiotic initiation",
"timeFrame": "3 months"
},
{
"description": null,
"measure": "Antibiotic duration",
"timeFrame": "3 months"
}
],
"secondary": [
{
"description": null,
"mea... | [
{
"affiliation": "ICES",
"name": "Nick Daneman, MD",
"role": "PRINCIPAL_INVESTIGATOR"
}
] | [{"pmid": "33754632", "type": "DERIVED", "citation": "Daneman N, Lee SM, Bai H, Bell CM, Bronskill SE, Campitelli MA, Dobell G, Fu L, Garber G, Ivers N, Lam JMC, Langford BJ, Laur C, Morris A, Mulhall C, Pinto R, Saxena FE, Schwartz KL, Brown KA. Population-Wide Peer Comparison Audit and Feedback to Reduce Antibiotic I... | {"versionHolder": "2025-06-18"} | null | {
"ancestors": null,
"browseBranches": [
{
"abbrev": "Infe",
"name": "Anti-Infective Agents"
},
{
"abbrev": "All",
"name": "All Drugs and Chemicals"
}
],
"browseLeaves": [
{
"asFound": null,
"id": "M4222",
"name": "Anti-Bacterial Agents",
"rele... | {
"conditions": null,
"interventions": []
} |
NCT04868266 | null | End Tidal Carbon Dioxide in Minimal Sedation | A Randomized Controlled Trial of the Effect of Capnography for Preventing Hypoxia in Minimally Sedated Pediatric Patients | ETCO2 | INTERVENTIONAL | ACTIVE_NOT_RECRUITING | 2021-04-25T00:00:00 | null | 2024-04-30T00:00:00 | 2024-12-30T00:00:00 | [
"NA"
] | 214 | null | 18 | ALL | false | This randomized controlled study investigated the effect of end-tidal carbon dioxide monitoring in pediatric patients undergoing minimal sedation. | null | Inclusion Criteria:
* pediatric patients undergoing minimal sedation for procedure.
Exclusion Criteria:
* none | Seoul National University Hospital | OTHER | {
"id": "D-2103-187-1208",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2021-04-27T00:00:00 | {
"date": "2024-05-31",
"type": "ACTUAL"
} | {
"date": "2021-04-30",
"type": "ACTUAL"
} | [
"CHILD",
"ADULT"
] | null | null | null | {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "PREVENTION",
"timePerspective": null
} | [
"Complication of Anesthesia"
] | null | null | [
{
"city": "Seoul",
"country": "Korea, Republic of",
"facility": "Jin-Tae Kim",
"geoPoint": {
"lat": 37.566,
"lon": 126.9784
},
"state": null
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Incidence of oxygen desaturation",
"timeFrame": "from immediately after sedation to end of procedure, up to 2 hours"
}
],
"secondary": [
{
"description": null,
"measure": "number of Staff intervetions",
... | null | null | {"versionHolder": "2025-06-18"} | {
"ancestors": null,
"browseBranches": [
{
"abbrev": "BC23",
"name": "Symptoms and General Pathology"
},
{
"abbrev": "All",
"name": "All Conditions"
}
],
"browseLeaves": [
{
"asFound": null,
"id": "M4185",
"name": "Hypoxia",
"relevance": "LOW"
... | null | {
"conditions": [],
"interventions": null
} |
NCT06147466 | null | Time Spent In Target Glucose Range in Women With T2D Diabetes in Pregnancy | Time Spent In the Target Glucose Range and MatErnaL and Neonatal Effects in Women With tYpe 2 Diabetes in Pregnancy (TIMELY) | Timely | OBSERVATIONAL | RECRUITING | 2023-04-03T00:00:00 | null | 2026-03-01T00:00:00 | 2026-06-01T00:00:00 | null | 50 | 18 | null | FEMALE | true | Prospective cohort study to determine to what extent women with type 2 diabetes are achieving the time in the target range outlined for women with type 1 diabetes (70-140 mg/dl or 3.5-7.8 mmol/l), overall and by trimester, by standard CGM measures and functional data analysis | null | Inclusion Criteria:
1. Women with type 2 diabetes diagnosed prior to pregnancy or prior to 20 weeks gestation with either a HbA1c of \>6.5%, fasting glucose ≥7.0, or 2 hr glucose ≥11.1 on a 75g OGTT. To make the diagnosis in pregnancy one needs 2 values equal to or greater than the values above.
2. ≤14 weeks gestation... | Mount Sinai Hospital, Canada | OTHER | {
"id": "21-0065-E",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2023-11-21T00:00:00 | {
"date": "2024-03-20",
"type": "ACTUAL"
} | {
"date": "2023-11-27",
"type": "ACTUAL"
} | [
"ADULT",
"OLDER_ADULT"
] | Pregnant Women with Type 2 diabetes with either a HbA1c of \>6.5%, fasting glucose ≥7.0, or 2 hr glucose ≥11.1 on a 75g OGTT | NON_PROBABILITY_SAMPLE | false | {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
} | [
"Diabete Type 2",
"Pregnancy in Diabetic"
] | ["glucose range", "neonatal outcomes", "glycemic control", "hypoglycemia", "insulin resistance", "preganant", "pregnancy", "CGM", "Continuous Glucose Monitoring", "Dexcom", "maternal outcomes", "Pregnancy in Diabetes"] | null | [
{
"city": "Toronto",
"country": "Canada",
"facility": "Mount Sinai Hospital",
"geoPoint": {
"lat": 43.70011,
"lon": -79.4163
},
"state": "Ontario"
}
] | [
{
"class": "OTHER",
"name": "University of Manitoba"
},
{
"class": "OTHER",
"name": "Women's College Hospital"
}
] | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Time in target range",
"timeFrame": "7-9 months"
}
],
"secondary": [
{
"description": null,
"measure": "Delivery outcome",
"timeFrame": "7-9 months"
},
{
"description": null,
"mea... | [
{
"affiliation": "Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital",
"name": "Denice Feig",
"role": "PRINCIPAL_INVESTIGATOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D003920",
"term": "Diabetes Mellitus"
},
{
"id": "D044882",
"term": "Glucose Metabolism Disorders"
},
{
"id": "D008659",
"term": "Metabolic Diseases"
},
{
"id": "D004700",
"term": "Endocrine System Diseases"
},
... | {
"ancestors": null,
"browseBranches": [
{
"abbrev": "Hypo",
"name": "Hypoglycemic Agents"
},
{
"abbrev": "All",
"name": "All Drugs and Chemicals"
}
],
"browseLeaves": [
{
"asFound": null,
"id": "M10365",
"name": "Insulin",
"relevance": "LOW"
... | {
"conditions": [
{
"id": "D011254",
"term": "Pregnancy in Diabetics"
},
{
"id": "D016640",
"term": "Diabetes, Gestational"
},
{
"id": "D003924",
"term": "Diabetes Mellitus, Type 2"
}
],
"interventions": []
} |
NCT05279066 | null | Validation of Ejection Fraction and Cardiac Output Using Biostrap Wristband | A Clinical Validation Study for Measuring Cardiac Output and Ejection Fraction Using a Wrist-worn Device. | None | OBSERVATIONAL | UNKNOWN | 2022-01-27T00:00:00 | null | 2022-07-15T00:00:00 | 2022-07-15T00:00:00 | null | 100 | 18 | null | ALL | true | In this study, the investigators will compare the accuracy of the Biostrap wristband, a wearable device with a clinical-grade Photoplethysmography (PPG) sensor, to measure ejection fraction and cardiac output in patients undergoing a cardiac ultrasound and pulmonary arterial catheterization, respectively. | This in an introductory clinical study with both cardiac patients undergoing elective cardiac ultrasound and cardiac ICU patients with pulmonary arterial catheters featuring Biostrap wristband. This is a single site, non-blinded, non-randomized study. The wristband is a wearable device that contains a clinical-grade Ph... | Inclusion Criteria:
1. ≥ 18 years of age.
2. Subjects who are undergoing elective cardiac ultrasound as an outpatient for group 1 or are scheduled for/completed a pilmonary arterial catheterization for group 2.
3. Written informed consent obtained from subject and ability for subject to comply with the requirements of... | University of California, Los Angeles | OTHER | {
"id": "21-001030",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2022-03-03T00:00:00 | {
"date": "2022-03-15",
"type": "ACTUAL"
} | {
"date": "2022-03-15",
"type": "ACTUAL"
} | [
"ADULT",
"OLDER_ADULT"
] | Men and woman over the age of 18 years old. | NON_PROBABILITY_SAMPLE | false | {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
} | [
"Heart Failure"
] | ["ejection fraction", "cardiac output"] | null | [
{
"city": "Los Angeles",
"country": "United States",
"facility": "Ronald Reagan UCLA Medical Center",
"geoPoint": {
"lat": 34.05223,
"lon": -118.24368
},
"state": "California"
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Association between obtained PPG waveforms and recorded ejection (EF) fractions",
"timeFrame": "6 months"
},
{
"description": null,
"measure": "Association between obtained PPG waveforms and recorded cardiac o... | null | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D006331",
"term": "Heart Diseases"
},
{
"id": "D002318",
"term": "Cardiovascular Diseases"
}
],
"browseBranches": [
{
"abbrev": "BC14",
"name": "Heart and Blood Diseases"
},
{
"abbrev": "All",
"name": "All Condit... | {
"ancestors": null,
"browseBranches": [
{
"abbrev": "Infe",
"name": "Anti-Infective Agents"
},
{
"abbrev": "All",
"name": "All Drugs and Chemicals"
}
],
"browseLeaves": [
{
"asFound": null,
"id": "M11767",
"name": "Metronidazole",
"relevance":... | {
"conditions": [
{
"id": "D006333",
"term": "Heart Failure"
}
],
"interventions": []
} |
NCT06874166 | null | Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders | Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders. Behavioural and Psychophisiological Measures | None | OBSERVATIONAL | NOT_YET_RECRUITING | 2025-02-17T00:00:00 | null | null | null | null | 45 | 4 | null | MALE | true | The primary aim of this observational study is to investigate specific aspects of social cognition in dystrophinopathies. Body awareness, interpersonal distance and emotional processing will be measured in a sample of patients affected by Becker (BMD) and Duchenne (DMD) muscular dystrophy, compared with a sample of pat... | Study procedure includes: 1. Eligibility assessment according to inclusion and exclusion criteria. 2. Administration of questionnaires and scales for the characterization of cognitive and psychological features related with BMD/DMD and OI : Wechsler Intelligence Scale for Children 4th Edition (WISC-IV), Raven's Progres... | Inclusion Criteria:
* Patients diagnosed with Duchenne and Becker muscular dystrophy (genetic and histological diagnosis and clinical diagnosis) (ambulant and non-ambulant).
* Patients diagnosed with osteogenesis imperfecta.
* Control group: participants without any neurological or psychiatric disorder
Exclusion Crit... | IRCCS Eugenio Medea | OTHER | {
"id": "L2-227",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2025-03-11T00:00:00 | {
"date": "2025-03-13",
"type": "ACTUAL"
} | {
"date": "2025-03-13",
"type": "ACTUAL"
} | [
"CHILD",
"ADULT",
"OLDER_ADULT"
] | For the statistical power analysis the size of the effect reported in Candini et al., 2017 (η2p = 0.28) has been considered, about the effect of diagnostic features on the peripersonal space, and the effect reported by Garcia et al., 2023 (η2p = 0.20) about the differences between DMD/BMD patients and neurotypicals in ... | NON_PROBABILITY_SAMPLE | false | {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "CASE_CONTROL",
"primaryPurpose": null,
"timePerspective": "CROSS_SECTIONAL"
} | [
"Duchenne / Becker Muscular Dystrophy",
"Osteogenesis Imperfecta (OI)",
"Social Cognition"
] | ["Social Cognition", "Duchenne / Becker muscular dystrophy", "Osteogenesis Imperfecta (OI)", "EEG", "Interpersonal distance", "Interoception"] | null | null | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Interoception",
"timeFrame": "Day 1"
},
{
"description": null,
"measure": "Interpersonal distance",
"timeFrame": "Day 1"
},
{
"description": null,
"measure": "Emotional processing",
... | null | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D020966",
"term": "Muscular Disorders, Atrophic"
},
{
"id": "D009135",
"term": "Muscular Diseases"
},
{
"id": "D009140",
"term": "Musculoskeletal Diseases"
},
{
"id": "D009468",
"term": "Neuromuscular Diseases"
}... | null | {
"conditions": [
{
"id": "D009136",
"term": "Muscular Dystrophies"
},
{
"id": "D020388",
"term": "Muscular Dystrophy, Duchenne"
},
{
"id": "D010013",
"term": "Osteogenesis Imperfecta"
},
{
"id": "D065886",
"term": "Neurodevelopmental Disorde... |
NCT06580366 | null | Comparing Sennosid A+B and Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation | Sennosid A+B Versus Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation; A Prospective Randomized Observer-Blinded Study | None | INTERVENTIONAL | NOT_YET_RECRUITING | 2024-08-27T00:00:00 | null | 2024-12-22T00:00:00 | 2025-03-22T00:00:00 | [
"PHASE4"
] | 600 | 18 | 80 | ALL | false | Colonoscopy Preparation: Comparing Sennoside A+B and PM/Ca
Colonoscopy is a test used to examine the inside of the bowel. Proper bowel preparation is crucial because it helps doctors get a clear view during the procedure.
What is Sennoside A+B? Sennoside A+B is a type of laxative made from the senna plant. It works b... | Colonoscopy is an endoscopic imaging method used to examine the lumen and mucosa of the bowel. It is the gold standard method used for colorectal cancer screening and the detection of most colorectal pathologies. Successful bowel preparation is one of the key factors for a successful colonoscopic examination.
Sennosid... | Inclusion Criteria:
* Adults aged 18-80 years scheduled for elective outpatient colonoscopy.
* Ability to provide informed consent.
Exclusion Criteria:
* History of intra-abdominal surgery.
* Chronic kidney failure.
* Congestive heart failure.
* Chronic liver failure.
* Inflammatory bowel disease.
* Electrolyte imba... | Hitit University | OTHER | {
"id": "HititUniversity-2024-43",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2024-08-28T00:00:00 | {
"date": "2024-08-30",
"type": "ACTUAL"
} | {
"date": "2024-08-30",
"type": "ACTUAL"
} | [
"ADULT",
"OLDER_ADULT"
] | null | null | false | {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "SINGLE",
"maskingDescription": null,
"whoMasked": [
"INVESTIGATOR"
]
},
"observationalModel": null,
"primaryPurpose": "SCREENING",
"timePerspective": nu... | [
"Bowel Preparation"
] | ["Bowel preparation", "Colonoscopy", "sennosid A+B", "Sodium Picosulfate"] | null | [
{
"city": "Çorum",
"country": "Turkey",
"facility": "Hitit University Erol Olcok Training and Research Hospital",
"geoPoint": {
"lat": 40.54889,
"lon": 34.95333
},
"state": null
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Sennosid A+B versus Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation: A Prospective Randomized Observer-Blinded Study",
"timeFrame": "4 months"
}
],
"secondary": null
} | [
{
"affiliation": "Hitit University",
"name": "İbrahim Durak",
"role": "STUDY_CHAIR"
}
] | [{"pmid": "24659864", "type": "BACKGROUND", "citation": "Park S, Lim YJ. Adjuncts to colonic cleansing before colonoscopy. World J Gastroenterol. 2014 Mar 21;20(11):2735-40. doi: 10.3748/wjg.v20.i11.2735."}, {"pmid": "32424868", "type": "BACKGROUND", "citation": "Coskun Y, Yuksel I. Polyethylene glycol versus split hig... | {"versionHolder": "2025-06-18"} | null | {
"ancestors": [
{
"id": "D000863",
"term": "Antacids"
},
{
"id": "D045504",
"term": "Molecular Mechanisms of Pharmacological Action"
},
{
"id": "D005765",
"term": "Gastrointestinal Agents"
},
{
"id": "D000925",
"term": "Anticoagulants"
}... | {
"conditions": null,
"interventions": [
{
"id": "D008277",
"term": "Magnesium Oxide"
},
{
"id": "C005701",
"term": "Picosulfate sodium"
},
{
"id": "D019343",
"term": "Citric Acid"
},
{
"id": "D000077559",
"term": "Sodium Citrate"
}
]... |
NCT05371366 | null | The Puncturable Atrial Septal Defect Occluder Trial (the PASSER Trial) | A Multicenter, Randomized, Parallel-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Atrial Septal Defect Occluder, ReAces®, and Delivery System for the Treatment of Atrial Septal Defect Occlusion | None | INTERVENTIONAL | UNKNOWN | 2022-05-04T00:00:00 | null | 2023-04-22T00:00:00 | 2023-04-22T00:00:00 | [
"NA"
] | 128 | 18 | 70 | ALL | false | A multicenter, randomized, parallel-controlled clinical trial to evaluate the efficacy and safety of a new atrial septal defect occluder, ReAces®, and delivery system for the treatment of atrial septal defect occlusion. Compared with the traditional atrial septal occluder, this new atrial septal occluder supports re-pu... | null | Inclusion Criteria:
1. aged 18-70 years;
2. with congenital secundum atrial septal defect;
3. the maximal ASD diameter was ≤38 mm;
4. with atrial-level left-to-right shunt, with Qp/Qs shunt ratio ≥1.5:1, or TTE or clinical manifestations indicated the existence of defect that inducing overfilling of right atrium;
5. t... | Shanghai Zhongshan Hospital | OTHER | {
"id": "HYYL2022-06ZC-01",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2022-05-07T00:00:00 | {
"date": "2022-05-24",
"type": "ACTUAL"
} | {
"date": "2022-05-12",
"type": "ACTUAL"
} | [
"ADULT",
"OLDER_ADULT"
] | null | null | null | {
"allocation": "RANDOMIZED",
"interventionModel": "PARALLEL",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
} | [
"Atrial Septal Defect"
] | null | null | [
{
"city": "Shanghai",
"country": "China",
"facility": "180 Fenglin Road",
"geoPoint": {
"lat": 31.22222,
"lon": 121.45806
},
"state": "Shanghai"
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Successful rate of complete closure of atrial septal defect",
"timeFrame": "0-360 days"
}
],
"secondary": [
{
"description": null,
"measure": "Adverse events",
"timeFrame": "0-360 days"
}
]
} | null | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D006330",
"term": "Heart Defects, Congenital"
},
{
"id": "D018376",
"term": "Cardiovascular Abnormalities"
},
{
"id": "D002318",
"term": "Cardiovascular Diseases"
},
{
"id": "D006331",
"term": "Heart Diseases"
},... | null | {
"conditions": [
{
"id": "D006343",
"term": "Heart Septal Defects"
},
{
"id": "D006344",
"term": "Heart Septal Defects, Atrial"
}
],
"interventions": null
} |
NCT00992966 | null | Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms | Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms. | None | OBSERVATIONAL | SUSPENDED | 2009-10-08T00:00:00 | null | null | null | null | 80 | 3 | 18 | ALL | false | The VRI device may provide a complementary diagnostic tool for lung examination and aid the physician in determining whether a chest x-ray should be performed. | This study is a prospective, single center study to determine the value of VRI images as an aid in determining whether a chest x ray is necessary to evaluate children presenting with acute respiratory complaints.
Study participants will be children, selected from the Emergency Department (ED), who were designated to u... | Inclusion Criteria:
1. Subject's parent or legal guardian, is able and willing to read the Informed Consent, understands the Informed Consent, and provides written Informed Consent for the subject; if the minor child is in fact able to give consent, the minor's consent must be obtained in addition to the consent of th... | Deep Breeze | INDUSTRY | {
"id": "DB048",
"link": null,
"type": null
} | Study initiation has been delayed due to Sponsor decision | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2009-10-08T00:00:00 | {
"date": "2010-08-20",
"type": "ESTIMATED"
} | {
"date": "2009-10-09",
"type": "ESTIMATED"
} | [
"CHILD",
"ADULT"
] | A total number of 80 patients in the age range of 3-18 and consisting of both boys and girls, preferably in an equal distribution | PROBABILITY_SAMPLE | true | {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
} | [
"Pneumonia"
] | ["to acquire database of pneumonia cases in children"] | null | null | null | null | null | [
{
"affiliation": "Shnider medical center",
"name": "Liora Kornreich, M.D",
"role": "PRINCIPAL_INVESTIGATOR"
},
{
"affiliation": "Shnider medical center",
"name": "Liora Kornreich, Professor",
"role": "PRINCIPAL_INVESTIGATOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D012141",
"term": "Respiratory Tract Infections"
},
{
"id": "D007239",
"term": "Infections"
},
{
"id": "D008171",
"term": "Lung Diseases"
},
{
"id": "D012140",
"term": "Respiratory Tract Diseases"
}
],
"brows... | null | {
"conditions": [
{
"id": "D011014",
"term": "Pneumonia"
},
{
"id": "D012818",
"term": "Signs and Symptoms, Respiratory"
}
],
"interventions": null
} |
NCT03829566 | null | Autologous Transplant To End NMO Spectrum Disorder | Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD) | ATTEND | INTERVENTIONAL | WITHDRAWN | 2019-02-01T00:00:00 | null | null | 2025-11-28T00:00:00 | [
"PHASE2",
"PHASE3"
] | 0 | 18 | 65 | ALL | false | This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term remission. | The autologous stem cell transplant used in this research study is an investigational procedure that uses cyclophosphamide (chemotherapy), rabbit antithymocyte globulin (rATG) (a protein that kills the immune cells that are thought to be causing your disease), rituximab (a biologic drug that targets B cells of your imm... | Inclusion Criteria:
1. Age 18 - 65 years old at the time of pre-transplant evaluation
2. An established diagnosis of NMOSD (with or without aquaporin 4 (AQP4)-IgG antibody)
Exclusion Criteria:
1. Under age of 18 or over age of 65
2. Prisoners
3. Psychiatric illness or mental deficiency making compliance with treatme... | Northwestern University | OTHER | {
"id": "DIAD.ATTEND.2018",
"link": null,
"type": null
} | Discontinued by Investigator | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2019-02-01T00:00:00 | {
"date": "2019-11-20",
"type": "ACTUAL"
} | {
"date": "2019-02-04",
"type": "ACTUAL"
} | [
"ADULT",
"OLDER_ADULT"
] | null | null | true | {
"allocation": "NA",
"interventionModel": "SINGLE_GROUP",
"interventionModelDescription": null,
"maskingInfo": {
"masking": "NONE",
"maskingDescription": null,
"whoMasked": null
},
"observationalModel": null,
"primaryPurpose": "TREATMENT",
"timePerspective": null
} | [
"Neuromyelitis Optica",
"Devic's Disease",
"NMO Spectrum Disorder"
] | ["Autologous Stem Cell Transplantation", "Hematopoietic Stem Cell Transplant"] | null | [
{
"city": "Chicago",
"country": "United States",
"facility": "Northwestern University, Feinberg School of Medicine",
"geoPoint": {
"lat": 41.85003,
"lon": -87.65005
},
"state": "Illinois"
},
{
"city": "Chicago",
"country": "United States",
"facility": "Northwester... | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "Progression-Free Survival",
"timeFrame": "5 years"
}
],
"secondary": [
{
"description": null,
"measure": "Relapse-Free Survival",
"timeFrame": "5 years"
},
{
"description": null,
... | [
{
"affiliation": "Northwestern University",
"name": "Richard Burt, MD",
"role": "PRINCIPAL_INVESTIGATOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D009188",
"term": "Myelitis, Transverse"
},
{
"id": "D020278",
"term": "Demyelinating Autoimmune Diseases, CNS"
},
{
"id": "D020274",
"term": "Autoimmune Diseases of the Nervous System"
},
{
"id": "D009422",
"term": ... | {
"ancestors": [
{
"id": "D007166",
"term": "Immunosuppressive Agents"
},
{
"id": "D007155",
"term": "Immunologic Factors"
},
{
"id": "D045505",
"term": "Physiological Effects of Drugs"
},
{
"id": "D018501",
"term": "Antirheumatic Agents"
... | {
"conditions": [
{
"id": "D009471",
"term": "Neuromyelitis Optica"
}
],
"interventions": [
{
"id": "D008775",
"term": "Methylprednisolone"
},
{
"id": "D000077555",
"term": "Methylprednisolone Acetate"
},
{
"id": "D008776",
"term": "Methy... |
NCT05046366 | null | Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology. | Research and Development of an Artificial Intelligence Technology System for Digital Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology. | None | OBSERVATIONAL | UNKNOWN | 2021-06-27T00:00:00 | null | null | null | null | 1,000 | 18 | 90 | ALL | true | To improve accurate diagnosis and treatment of common malignant tumors and major infectious diseases in the respiratory system, we aim to establish a large medical database that includes standardized and structured clinical diagnosis and treatment information such as electronic medical records, image features, patholog... | The main aims are as follows:
1. To establish a medical big data platform for multi-modal information fusion of common tumors and major infectious diseases (lung cancer/pulmonary nodules, tuberculosis, and COVID-19) based on the existing pathological image features and clinical multi-omics information database: The me... | Inclusion Criteria:
1. Participants with the clinical diagnosis of lung cancer, pulmonary tuberculosis, and COVID-19.
2. Participants that have signed informed consent.
3. Participants \>= 18 years old and \< 90 years old.
4. Participants with detailed electronic medical records, image records, pathological records, m... | Wuhan Union Hospital, China | OTHER | {
"id": "[2021]IEC(491)",
"link": null,
"type": null
} | Unknown | {
"hasExpandedAccess": false,
"nctId": null,
"statusForNctId": null
} | 2021-09-15T00:00:00 | {
"date": "2021-11-16",
"type": "ACTUAL"
} | {
"date": "2021-09-16",
"type": "ACTUAL"
} | [
"ADULT",
"OLDER_ADULT"
] | Common malignant tumors and major infectious diseases in lung, including lung cancer, pulmonary tuberculosis, and COVID-19. | NON_PROBABILITY_SAMPLE | null | {
"allocation": null,
"interventionModel": null,
"interventionModelDescription": null,
"maskingInfo": null,
"observationalModel": "COHORT",
"primaryPurpose": null,
"timePerspective": "PROSPECTIVE"
} | [
"Artificial Intelligence",
"Deep Learning",
"Pathology, Molecular",
"Medical Informatics",
"Database",
"Lung Cancer",
"Pulmonary Tuberculosis",
"Covid19"
] | null | null | [
{
"city": "Wuhan",
"country": "China",
"facility": "Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",
"geoPoint": {
"lat": 30.58333,
"lon": 114.26667
},
"state": "Hubei"
}
] | null | null | {
"other": null,
"primary": [
{
"description": null,
"measure": "The outcome of clinical diagnosis of suspected patients with lung cancer/pulmonary nodular (Benign/Malignant nodule).",
"timeFrame": "2021-2024"
},
{
"description": null,
"measure": "The outcome of clinical di... | [
{
"affiliation": "union hospital, Tongji Medical college, Huazhonguniversity of science and technology",
"name": "Yang Jin, Professor",
"role": "STUDY_DIRECTOR"
}
] | null | {"versionHolder": "2025-06-18"} | {
"ancestors": [
{
"id": "D009164",
"term": "Mycobacterium Infections"
},
{
"id": "D000193",
"term": "Actinomycetales Infections"
},
{
"id": "D016908",
"term": "Gram-Positive Bacterial Infections"
},
{
"id": "D001424",
"term": "Bacterial Infe... | {
"ancestors": null,
"browseBranches": [
{
"abbrev": "Resp",
"name": "Respiratory System Agents"
},
{
"abbrev": "All",
"name": "All Drugs and Chemicals"
}
],
"browseLeaves": [
{
"asFound": null,
"id": "M21137",
"name": "Respiratory System Agents",
... | {
"conditions": [
{
"id": "D014376",
"term": "Tuberculosis"
},
{
"id": "D003141",
"term": "Communicable Diseases"
},
{
"id": "D007239",
"term": "Infections"
},
{
"id": "D014397",
"term": "Tuberculosis, Pulmonary"
}
],
"interventions":... |
Clinical Trials Dataset
A comprehensive dataset of clinical trials sourced from ClinicalTrials.gov, featuring structured metadata, detailed study information, and pre-computed semantic embeddings for machine learning applications in biomedical research.
Dataset Description
This dataset provides a rich collection of clinical trial information systematically collected from the official ClinicalTrials.gov database. Each record contains detailed study metadata, eligibility criteria, intervention descriptions, outcome measures, and organizational information. The dataset is enhanced with semantic embeddings generated using specialized biomedical language models, making it immediately ready for downstream ML tasks.
Key Features
- Comprehensive Coverage: Complete clinical trial records with 30+ structured fields
- Rich Metadata: Study phases, enrollment data, eligibility criteria, and outcome measures
- Temporal Data: Complete timeline information from submission to completion
- Medical Ontology: MeSH terms and condition/intervention classifications
Dataset Statistics
| Metric | Value |
|---|---|
| Total Studies | 500,000+ |
| Data Source | ClinicalTrials.gov Official API |
| Languages | English |
Data Collection Methodology
The dataset is built using a robust data pipeline that ensures data quality and consistency:
- API Integration: Direct connection to ClinicalTrials.gov API v2
- Data Validation: Pydantic models ensure schema compliance and data integrity
- Type Conversion: Automatic parsing of dates, numbers, and JSON structures
- Embedding Generation: Semantic embeddings computed using domain-specific models
Data Quality Assurance
- Schema Validation: All records validated against comprehensive Pydantic models
- Type Safety: Proper data type conversion with null handling
- Deduplication: Unique constraint on NCT ID prevents duplicates
- Temporal Consistency: Date validation and chronological ordering
- Text Normalization: Whitespace cleanup and encoding standardization
Schema Overview
Core Study Information
nct_id: Unique study identifier (NCT########)brief_title: Concise study titleofficial_title: Complete formal study titlestudy_type: Study design type (Interventional, Observational, etc.)phases: Clinical trial phases (Phase I, II, III, IV)overall_status: Current study status
Study Design & Population
enrollment_count: Target or actual enrollment numberminimum_age/maximum_age: Age eligibility boundssex: Gender eligibility (All, Male, Female)healthy_volunteers: Whether healthy volunteers acceptedeligibility_criteria: Detailed inclusion/exclusion criteriastudy_population: Target population description
Clinical Context
conditions: Medical conditions studiedkeywords: Study-related keywordsbrief_summary: Study purpose and rationaledetailed_description: Comprehensive study descriptionprimary_outcomes/secondary_outcomes: Measured endpoints
Organizational Information
lead_sponsor: Primary study sponsorcollaborators: Additional supporting organizationslocations: Study sites with geographic coordinatesoverall_officials: Principal investigators and study officials
Temporal Data
study_first_submit_date: Initial submission to ClinicalTrials.govstart_date: Study start dateprimary_completion_date: Primary endpoint completioncompletion_date: Overall study completionlast_update_submit_date: Most recent data update
Enhanced Features
brief_summary_embedding: 768-dim semantic embedding of study summaryeligibility_criteria_embedding: 768-dim embedding of eligibility text
Usage Examples
Basic Data Loading
from datasets import load_dataset
# Load the complete dataset
dataset = load_dataset("louisbrulenaudet/clinical-trials")
# Access train split
train_data = dataset["train"]
print(f"Dataset size: {len(train_data)}")
print(f"Features: {train_data.features}")
Advanced usage and embeddings
from datasets import load_dataset
from sentence_transformers import SentenceTransformer
model = SentenceTransformer(
"thomas-sounack/BioClinical-ModernBERT-base", device="cuda", model_kwargs={"torch_dtype": "float16"}
)
dataset = load_dataset("louisbrulenaudet/clinical-trials", split="train")
columns_to_embed = [
"brief_summary",
"eligibility_criteria"
]
def embed_texts(batch):
for col in columns_to_embed:
embeddings = model.encode(batch[col], convert_to_numpy=True, normalize_embeddings=True)
batch[f"{col}_embedding"] = embeddings.tolist()
return batch
embedded_dataset = hf_dataset.map(
embed_texts,
batched=True,
batch_size=512,
desc="Embedding columns"
)
Applications
This dataset enables various research and development applications:
Clinical Research
- Study Landscape Analysis: Understanding research trends and gaps
- Protocol Optimization: Learning from successful study designs
- Site Selection: Geographic analysis for multi-center trials
- Regulatory Intelligence: Phase progression and approval patterns
Machine Learning
- Text Classification: Categorizing studies by therapeutic area
- Information Extraction: Parsing eligibility criteria and outcomes
- Similarity Search: Finding related studies using embeddings
- Trend Prediction: Forecasting research directions
Healthcare Analytics
- Disease Burden Analysis: Understanding research investment by condition
- Innovation Tracking: Monitoring emerging therapies and interventions
- Collaboration Networks: Analyzing sponsor and investigator relationships
- Geographic Health Mapping: Regional research activity patterns
Data Limitations & Considerations
Coverage Limitations
- Source Dependency: Limited to studies registered on ClinicalTrials.gov
- Registration Bias: Not all studies worldwide are required to register
- Temporal Scope: Historical data quality varies by submission period
- Language: Primarily English-language studies
Data Quality Notes
- Self-Reported: Information accuracy depends on sponsor reporting
- Update Lag: Some studies may have outdated status information
- Completeness: Optional fields may be sparse for older studies
- Standardization: Free-text fields may lack consistent formatting
Ethical Considerations
- Privacy: No individual participant data included
- Transparency: Enhances clinical research transparency
- Research Bias: May reflect existing healthcare disparities
- Access: Promotes equitable access to clinical research information
Licensing & Attribution
Dataset License
This dataset is released under the MIT License, allowing for both academic and commercial use with proper attribution.
Source Attribution
- Primary Source: ClinicalTrials.gov (https://clinicaltrials.gov/)
- API: ClinicalTrials.gov API v2
Citation
If you use this dataset in your research, please cite:
@dataset{louisbrulenaudet2025,
title={Clinical Trials Dataset: Comprehensive ClinicalTrials.gov Data for Semantic analysis},
author={[Louis Brulé Naudet]},
year={2025},
publisher={Hugging Face},
url={https://huggingface.co/datasets/louisbrulenaudet/clinical-trials}
}
This dataset aims to accelerate biomedical research by providing easy access to comprehensive clinical trial information. We encourage responsible use that advances medical knowledge and improves patient outcomes.
Feedback
If you have any feedback, please reach out at louisbrulenaudet@icloud.com.
- Downloads last month
- 262